XML 67 R48.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Schedule of Segment Reporting Information, by Segment | The following table summarizes our segment revenue, significant segment expenses, and segment profit:
| 2024 |  | 2023 |  | 2022
Revenue | $ | 45,042.7 |  |  | $ | 34,124.1 |  |  | $ | 28,541.4 |
Less: |  |  |  |  |
Cost of sales | 8,418.3 |  |  | 7,082.2 |  |  | 6,629.8 |
Early-stage research and development(1) | 3,916.9 |  |  | 3,092.5 |  |  | 2,406.6 |
Late-stage research and development(1) | 7,073.7 |  |  | 6,220.9 |  |  | 4,784.2 |
Marketing, selling, and administrative | 8,593.8 |  |  | 7,403.1 |  |  | 6,440.4 |
Acquired in-process research and development | 3,280.4 |  |  | 3,799.8 |  |  | 908.5 |
Other segment items(2) | 3,169.6 |  |  | 1,285.2 |  |  | 1,127.1 |
Net income | $ | 10,590.0 |  |  | $ | 5,240.4 |  |  | $ | 6,244.8 |
(1) Early-stage research and development primarily includes costs incurred from discovery through Phase 2 clinical trials. Late-stage research and development primarily includes costs incurred from Phase 3 clinical trials. (2) Other segment items primarily include income taxes and asset impairment, restructuring, and other special charges. The following tables summarize additional segment information:
| 2024 |  | 2023 |  | 2022
Interest income | $ | 175.2 |  |  | $ | 173.6 |  |  | $ | 62.8 |
Interest expense | 780.6 |  |  | 485.9 |  |  | 331.6 |
Depreciation and amortization | 1,766.6 |  |  | 1,527.3 |  |  | 1,522.5 |
Asset impairment, restructuring, and other special charges | 860.6 |  |  | 67.7 |  |  | 244.6 |
Earnings (loss) in equity method investments | 89.8 |  |  | (10.1) |  |  | (138.0) |
Income taxes | 2,090.4 |  |  | 1,314.2 |  |  | 561.6 |
Expenditures for long-lived assets(1) | 5,560.8 |  |  | 3,830.2 |  |  | 2,289.2 |
(1) Includes expenditures for property and equipment and computer software costs.
| 2024 |  | 2023
Total assets | $ | 78,714.9 |  |  | $ | 64,006.3 |
Equity method investments | 1,142.7 |  |  | 962.3 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration